Cytek Biosciences, Inc.
Cytek Biosciences, Inc. (Nasdaq: CTKB) develops cell analysis instruments, reagents, software and services for biomedical research and clinical applications. Its Full Spectrum Profiling technology powers cell analyzers and sorters that measure multiple fluorescent signals to identify and isolate cell populations,… From the company’s description.
Over the twelve months to Sep 30, 2026, Cytek Biosciences, Inc. reported revenue of $207.65M, up 5.5% from a year earlier, and a net loss of $81.20M. Its operating margin was −21.1%, and operations used $6.59M in cash. In fiscal 2025, it reported revenue of $201.49M, up 0.5% from fiscal 2024, and a net loss of $66.54M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cytek Biosciences, Inc. does
In the company’s own words
Cytek Biosciences, Inc. (Nasdaq: CTKB) develops cell analysis instruments, reagents, software and services for biomedical research and clinical applications. Its Full Spectrum Profiling technology powers cell analyzers and sorters that measure multiple fluorescent signals to identify and isolate cell populations, while its broader portfolio includes imaging and conventional flow cytometers, sample-handling systems, assay kits and digital workflow tools. Customers include pharmaceutical and biotechnology companies, contract research organizations, academic and government institutions, and clinical laboratories. The company’s products support research in areas including oncology, immunology, infectious diseases and drug discovery. Its portfolio includes the Cytek Aurora, Northern Lights, Aurora CS, Amnis, Guava and Muse systems, along with cFluor and Tonbo reagents and SpectroFlo software. The Amnis and Guava businesses joined Cytek through a 2023 acquisition. Cytek reports one operating segment. Revenue was $201.5 million in fiscal 2025, and the company had more than 700 employees as of December 31, 2025. Its website is www.cytekbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- FREMONT, CA
- Fiscal year end
- December
- CIK
- 1831915
- SIC
- 3826
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cytek Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cytek Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cytek Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cytek Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cytek Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”